NEW YORK, May 1, 2017 /PRNewswire/ --
Stock-Callers.com has issued research reports on: The Medicines Co. (NASDAQ: MDCO), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), and Supernus Pharmaceuticals Inc. (NASDAQ: SUPN). According to Research and Markets' report titled, "Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry 2017," the US is the biggest Generic Drugs market in the world, with nearly 80% of prescriptions written in the country just for generics. Register now and get full and free access to our downloadable research reports on these stocks at:
Parsippany, New Jersey-based The Medicines Co.'s ("MDCO") shares recorded a trading volume of 1.05 million shares last Friday. The stock finished the trading session 1.52% higher at $49.32. The Company's shares have surged 41.24% over the previous three months and 45.32% since the start of this year. The stock is trading above its 200-day moving average by 20.89%. Furthermore, shares of MDCO, which provides medicines for patients in acute and intensive care hospitals worldwide, have a Relative Strength Index (RSI) of 41.80.
On April 26th, 2017, MDCO and Alnylam Pharmaceuticals, Inc. announced that the former has agreed with the US Food and Drug Administration (FDA) on plans for the Phase III clinical program for inclisiran, which is designed to support the submission of a New Drug Application. MDCO has received final, End-of-Phase II meeting minutes from the FDA. Access our complete research report on MDCO for free at:
On Friday, Cambridge, Massachusetts headquartered Ironwood Pharmaceuticals Inc.'s stock ended the session 0.37% lower at $16.32. A total volume of 736,441 shares was traded. The Company's shares have gained 16.82% over the previous three months and 6.74% on an YTD basis. The stock is trading 6.86% above its 200-day moving average. Moreover, shares of Ironwood Pharma, which engages in the research, development, and commercialization of human therapeutic products, have an RSI of 47.70.
On April 07th, 2017, research firm Mizuho reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $21 a share to $22 a share.
On April 24th, 2017, Ironwood Pharma announced that it will host its Q1 2017 investor update conference call and webcast at 8:30 a.m. ET on Monday, May 08th, 2017. The webcast may be accessed under the Investors section of the Company's website. The complimentary research report on IRWD can be downloaded at:
Parsippany, New Jersey headquartered Pacira Pharmaceuticals Inc.'s stock ended the day 1.04% higher at $48.55 with a total trading volume of 903,166 shares. The Company's shares have gained 2.00% in the last month, 30.34% over the previous three months, and 50.31% on an YTD basis. The stock is trading 4.58% and 23.37% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Pacira Pharma, which develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the US, have an RSI of 59.09.
On April 13th, 2017, research firm RBC Capital Markets initiated an 'Outperform' rating on the Company's stock, with a target price of $58 per share.
On April 27th, 2017, Pacira Pharma announced that it will report its Q1 financial results before the open of the US markets on Thursday, May 04th, 2017. The announcement will be followed by a conference call at 8:30 a.m. ET. Participating in the call will be Dave Stack, Chairman and CEO, and other members of the Company's senior management team. Register for free on Stock-Callers.com and get access to the latest PDF format report on PCRX at:
Shares in Rockville, Maryland-based Supernus Pharmaceuticals Inc. recorded a trading volume of 378,057 shares. The stock ended Friday's session 1.81% lower at $32.60. The Company's shares have gained 6.02% in the last month, 25.38% over the previous three months, and 29.11% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 11.35% and 31.96%, respectively. Furthermore, shares of Supernus Pharma, which focuses on the development and commercialization of products for the treatment of central nervous system diseases in the US, have an RSI of 61.94.
On April 26th, 2017, Supernus Pharma announced that it expects to report the financial results for Q1 2017 after 5:00 p.m. ET on Tuesday, May 09th, 2017. Jack Khattar, President and CEO, and Greg Patrick, CFO, will host a conference call to present Q1 2017 results on Wednesday, May 10th, 2017, at 9:00 a.m. ET. Download your free research report on SUPN at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA